Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Non-Current Assets (2016 - 2025)

United Therapeutics (UTHR) has disclosed Other Non-Current Assets for 17 consecutive years, with $196.9 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 11.35% to $196.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196.9 million through Dec 2025, down 11.35% year-over-year, with the annual reading at $196.9 million for FY2025, 11.35% down from the prior year.
  • Other Non-Current Assets hit $196.9 million in Q4 2025 for United Therapeutics, down from $262.6 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $262.6 million in Q3 2025 to a low of $105.8 million in Q2 2022.
  • Historically, Other Non-Current Assets has averaged $161.2 million across 5 years, with a median of $159.8 million in 2023.
  • Biggest five-year swings in Other Non-Current Assets: crashed 40.23% in 2022 and later skyrocketed 46.31% in 2024.
  • Year by year, Other Non-Current Assets stood at $108.2 million in 2021, then rose by 5.64% to $114.3 million in 2022, then surged by 32.81% to $151.8 million in 2023, then surged by 46.31% to $222.1 million in 2024, then decreased by 11.35% to $196.9 million in 2025.
  • Business Quant data shows Other Non-Current Assets for UTHR at $196.9 million in Q4 2025, $262.6 million in Q3 2025, and $233.3 million in Q2 2025.